CBD and the Immune System: Extensive Preclinical Evidence, Zero Clinical Trials
Across mice, rats, guinea pigs, and human cell experiments, CBD consistently suppressed innate immune responses — but no clinical trial has yet tested whether this translates to treating inflammatory diseases in humans.
Quick Facts
What This Study Found
CBD has FDA approval for epilepsy (Epidiolex), but its anti-inflammatory and immunomodulatory effects have attracted attention for conditions ranging from autoimmune diseases to COVID-19. This review cataloged what's actually known about how CBD affects the innate immune system — the body's first line of defense against pathogens and tissue damage.
The evidence base is extensive in preclinical models. Across experiments in mice, rats, guinea pigs, and human cells studied outside the body, CBD consistently reduced inflammatory responses: it decreased production of pro-inflammatory cytokines, reduced immune cell migration to sites of inflammation, and modulated the activity of macrophages, neutrophils, and natural killer cells. The effects were seen across multiple disease models, from sepsis to lung inflammation to neuroinflammation.
But here's the critical gap: as of this review, not a single clinical trial had tested CBD's immune-modulating effects in human patients with inflammatory diseases. All the evidence comes from animal models and ex vivo experiments on human cells. The translation from 'CBD reduces inflammation in a mouse' to 'CBD treats inflammatory disease in a person' remains completely untested.
The review also notes CBD's complex pharmacology — it acts through multiple receptors and pathways (CB2, GPR55, PPARγ, adenosine receptors, among others), making its immune effects difficult to predict and potentially variable depending on the disease context.
Key Numbers
CBD reduced pro-inflammatory cytokine production across multiple models. Effects were observed on macrophages, neutrophils, natural killer cells, and dendritic cells. CBD acts through CB2, GPR55, PPARγ, adenosine A2A, and TRPV1 receptors, among others. Zero clinical trials of CBD for inflammatory/immune conditions were identified as of the review date.
How They Did This
Narrative review of preclinical evidence for CBD's effects on innate immunity. Covered studies in mice, rats, guinea pigs, and ex vivo experiments on human immune cells. Examined effects on cytokine production, immune cell migration, macrophage function, neutrophil activity, and natural killer cell function across various disease models.
Why This Research Matters
The disconnect between preclinical promise and clinical evidence is a defining problem in CBD research. Millions of people use CBD products for inflammatory conditions — arthritis, autoimmune diseases, chronic pain — based largely on this preclinical evidence. This review makes clear that while the laboratory evidence is genuinely promising, the clinical evidence that would actually prove benefit in humans is completely absent.
The Bigger Picture
This review provides the immunological backdrop for several studies in the RethinkTHC database. The CBG inflammation study (RTHC-00097) works through partly overlapping pathways (TRPA1). The CBD drug interaction study (RTHC-00091) showed CBD's effects on liver enzymes, which is relevant because immune-modulating doses of CBD might also affect how patients metabolize other medications. The gap between preclinical promise and clinical evidence is a theme that runs through much of cannabis research.
What This Study Doesn't Tell Us
Narrative review, not systematic — may not capture all relevant preclinical literature. The biggest limitation is the one the authors themselves emphasize: no clinical trials exist. Animal immune responses differ from human ones in important ways, and many drugs that work brilliantly in mice fail in humans. The multi-receptor pharmacology of CBD means that immune effects observed in one context may not apply to others.
Questions This Raises
- ?Will CBD's immunosuppressive effects translate to clinical benefit in autoimmune diseases, or will they increase infection risk?
- ?At what doses do immune effects occur, and how do those compare to typical consumer CBD product doses?
- ?Could CBD's immune-modulating effects be harmful in some contexts (like during acute infections) even as they're helpful in others (like autoimmune flares)?
Trust & Context
- Key Stat:
- Evidence Grade:
- Narrative review of preclinical evidence. The animal and cell data are extensive and consistent, but the complete absence of clinical trials makes the evidence preliminary by definition. This is a hypothesis-generating review, not clinical guidance.
- Study Age:
- Published in 2023. Clinical trials testing CBD in inflammatory conditions may now be underway or recently completed.
- Original Title:
- Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance.
- Published In:
- International journal of molecular sciences, 24(4) (2023) — The International Journal of Molecular Sciences is a reputable peer-reviewed journal focusing on molecular biology and related fields.
- Authors:
- Martini, Stefano, Gemma, Alessandra, Ferrari, Marco(2), Cosentino, Marco, Marino, Franca
- Database ID:
- RTHC-04755
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04755APA
Martini, Stefano; Gemma, Alessandra; Ferrari, Marco; Cosentino, Marco; Marino, Franca. (2023). Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance.. International journal of molecular sciences, 24(4). https://doi.org/10.3390/ijms24043125
MLA
Martini, Stefano, et al. "Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance.." International journal of molecular sciences, 2023. https://doi.org/10.3390/ijms24043125
RethinkTHC
RethinkTHC Research Database. "Effects of Cannabidiol on Innate Immunity: Experimental Evid..." RTHC-04755. Retrieved from https://rethinkthc.com/research/martini-2023-effects-of-cannabidiol-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.